These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 15569618)
41. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151 [TBL] [Abstract][Full Text] [Related]
42. Human CD4+ T cells displaying viral epitopes elicit a functional virus-specific memory CD8+ T cell response. Adamopoulou E; Diekmann J; Tolosa E; Kuntz G; Einsele H; Rammensee HG; Topp MS J Immunol; 2007 May; 178(9):5465-72. PubMed ID: 17442927 [TBL] [Abstract][Full Text] [Related]
43. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide. Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040 [TBL] [Abstract][Full Text] [Related]
44. Role of APC in the selection of immunodominant T cell epitopes. Ma C; Whiteley PE; Cameron PM; Freed DC; Pressey A; Chen SL; Garni-Wagner B; Fang C; Zaller DM; Wicker LS; Blum JS J Immunol; 1999 Dec; 163(12):6413-23. PubMed ID: 10586031 [TBL] [Abstract][Full Text] [Related]
45. Extending antigen release from particulate vaccines results in enhanced antitumor immune response. Kapadia CH; Tian S; Perry JL; Sailer D; Christopher Luft J; DeSimone JM J Control Release; 2018 Jan; 269():393-404. PubMed ID: 29146244 [TBL] [Abstract][Full Text] [Related]
46. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells. Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105 [TBL] [Abstract][Full Text] [Related]
47. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice. Fifis T; Mottram P; Bogdanoska V; Hanley J; Plebanski M Vaccine; 2004 Nov; 23(2):258-66. PubMed ID: 15531045 [TBL] [Abstract][Full Text] [Related]
48. Native IgG2a(b) is barely antigenic to major histocompatibility complex class II-restricted T cells owing to inefficient internalization by professional antigen-presenting cells. Bartnes K; Hannestad K Immunology; 2000 Apr; 99(4):510-22. PubMed ID: 10792498 [TBL] [Abstract][Full Text] [Related]
49. Co-delivery of a CD4 T cell helper epitope via covalent liposome attachment with a surface-arrayed B cell target antigen fosters higher affinity antibody responses. Elbahnasawy MA; Donius LR; Reinherz EL; Kim M Vaccine; 2018 Oct; 36(41):6191-6201. PubMed ID: 30197285 [TBL] [Abstract][Full Text] [Related]
50. Major Histocompatibility Complex Class I (FLA-E*01801) Molecular Structure in Domestic Cats Demonstrates Species-Specific Characteristics in Presenting Viral Antigen Peptides. Liang R; Sun Y; Liu Y; Wang J; Wu Y; Li Z; Ma L; Zhang N; Zhang L; Wei X; Qu Z; Zhang N; Xia C J Virol; 2018 Mar; 92(6):. PubMed ID: 29263258 [TBL] [Abstract][Full Text] [Related]
51. Beta 2-microglobulin independent presentation of exogenously added foreign peptide and endogenous self-epitope by MHC class I alpha-chain to a cross-reactive CD8+ CTL clone. Zügel U; Schoel B; Kaufmann SH J Immunol; 1994 Nov; 153(9):4070-80. PubMed ID: 7523514 [TBL] [Abstract][Full Text] [Related]
52. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge. Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533 [TBL] [Abstract][Full Text] [Related]
53. Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis. Rosenthal KS; Mikecz K; Steiner HL; Glant TT; Finnegan A; Carambula RE; Zimmerman DH Expert Rev Vaccines; 2015 Jun; 14(6):891-908. PubMed ID: 25787143 [TBL] [Abstract][Full Text] [Related]
54. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. BenMohamed L; Bertrand G; McNamara CD; Gras-Masse H; Hammer J; Wechsler SL; Nesburn AB J Virol; 2003 Sep; 77(17):9463-73. PubMed ID: 12915561 [TBL] [Abstract][Full Text] [Related]
55. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315 [TBL] [Abstract][Full Text] [Related]
56. Altered major histocompatibility complex proteins and peptides for the induction of tolerance after organ transplantation. Shih-Chueh C; Kahan BD BioDrugs; 1998 May; 9(5):397-417. PubMed ID: 18020574 [TBL] [Abstract][Full Text] [Related]
57. The biochemistry and cell biology of antigen presentation by MHC class I and class II molecules. Implications for development of combination vaccines. Germain RN Ann N Y Acad Sci; 1995 May; 754():114-25. PubMed ID: 7625645 [TBL] [Abstract][Full Text] [Related]
59. Prediction and analysis of promiscuous T cell-epitopes derived from the vaccine candidate antigens of Leishmania donovani binding to MHC class-II alleles using in silico approach. Kashyap M; Jaiswal V; Farooq U Infect Genet Evol; 2017 Sep; 53():107-115. PubMed ID: 28549876 [TBL] [Abstract][Full Text] [Related]
60. Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines. Zimmerman DH; Szekanecz Z; Markovics A; Rosenthal KS; Carambula RE; Mikecz K Front Immunol; 2024; 15():1334281. PubMed ID: 38510240 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]